Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 0828 • ACR Convergence 2023
Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire
Maya Adams¹, Linda Hynan², Motolani Ogunsanya³ and Benjamin Chong¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peter O’Donnell Jr. School of Public Health and Department of Psychiatry, Dallas, TX, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Cutaneous lupus erythematosus (CLE) symptoms often require patient-reported outcome measures (PROMs) to monitor disease progression. The CLE quality of life (CLEQoL) instrument was devised…
Abstract Number: 0901 • ACR Convergence 2023
Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus
Jaya Krishnan¹, Néstor de la Visitación¹, Jonathan Williams¹, Leslie Crofford² and David Patrick³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Melbourne, AR, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Atherosclerosis and vascular inflammation are a cause of morbidity and mortality in systemic lupus erythematosus (SLE). Vascular NETosis is a driver of atherosclerosis and…
Abstract Number: 0918 • ACR Convergence 2023
Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Katie Heitzman¹, Sneha Dass¹, Linda Hiraki², Earl Silverman³, Christiaan Scott⁴, Ana Barrera-Vargas⁵, Zuoming Deng⁶, Mariana Kaplan⁷, Luis Franco⁸ and Laura Lewandowski⁹, ¹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Silverman, Toronto, ON, Canada, ⁴Paediatric Rheumatology, Red Cross War Memorial Children’s Hospital and University of Cape Town, Cape Town, South Africa, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁷Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁸Functional Immunogenomics Section, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, ⁹Lupus Genetics and Global Health Disparities Unit, Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…
Abstract Number: 1091 • ACR Convergence 2023
Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Raphael Kirou, Cesar Avalos and Ellen Ginzler, SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: Quality of care (QoC) in SLE patients has been studied by Schmajuk et al. (Arthritis Care Res2022), who developed six quality measures assessing blood…
Abstract Number: 1242 • ACR Convergence 2023
Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus
justine ledochowski¹, Sarah Mossad², Tala El Tal³, Victoria Lishak², Ibrahim Mohamed⁴, Joanna Law², Lawrence Ng², Paris Moaf², Asha Jeyanathan², Adrienne Davis², Linda Hiraki², Deborah Levy², Ashley Danguecan² and Andrea Knight², ¹Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁴The Hospital for Sick Children, Brampton, ON, Canada
Background/Purpose: Executive functions (EFs) are a set of cognitive skills that enable successful problem solving and goal-directed behavior. EFs are predictive of academic success, mental…
Abstract Number: 1444 • ACR Convergence 2023
Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study
Sook Yan Lee¹, Amelia Holloway², Elena Nikiphorou³, Ioannis Parodis⁴, Naveen R⁵, Jessica Day⁶, Mrudula Joshi⁷, Sreoshy Saha⁸, Kshitij Jagtap⁹, Wanruchada Katchamart¹⁰, Phonpen Akarawatcharangura Goo¹¹, Binit Vaidya¹², Tsvetelina Velikova¹³, Parikshit Sen¹⁴, Samuel Shinjo¹⁵, Vishwesh Agarwal¹⁶, Ai Lyn Tan¹⁷, Nelly Ziade¹⁸, Marcin Milchert¹⁹, Abraham Edgar Gracia-Ramos²⁰, Carlo Caballero²¹, COVAD Study Group²², Hector Chinoy²³, Vikas Agarwal⁵, Rohit Aggarwal²⁴, Latika Gupta²⁵ and Chris Wincup², ¹King's College Hospital, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, United Kingdom, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶Walter and Eliza Hall Institute, Melbourne, Australia, ⁷Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁸Mymensingh Medical College, Faridpur, Bangladesh, ⁹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹⁰Mahidol University, Bangkok, Thailand, ¹¹Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ¹²National Centre for Rheumatic Diseases, Kathmandu, Nepal, ¹³Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁴Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁵Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ¹⁷University of Leeds, Leeds, United Kingdom, ¹⁸Saint-Joseph University, Beirut, Lebanon, ¹⁹Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²⁰Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ²¹Universidad del Norte, Barranquilla, Colombia, ²²-, -, ²³The University of Manchester, Sale, United Kingdom, ²⁴University of Pittsburgh, Pittsburgh, PA, ²⁵Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) can result in impaired daily physical function through various mechanisms including active disease, chronic damage, and mental health symptoms that…
Abstract Number: 1461 • ACR Convergence 2023
Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL
Michelle Barraclough¹, Carolina Munoz-Grajales², Lauren Erdman³, Juan Pablo Diaz Martinez⁴, Kathleen Bingham¹, Mahta Kakvan⁵, Roberta Kretzmann⁶, Carmela Tartaglia⁷, Lesley Ruttan⁸, May Choi⁹, Simone Appenzeller¹⁰, Sherief Marzouk⁶, Dennisse Bonilla⁴, Patti Katz¹¹, Dorcas Beaton¹², Anna Goldenberg¹³, Robin Green⁶, Joan Wither¹ and Zahi Touma⁶, ¹University Health Network, Toronto, ON, Canada, ²UHN/TWH, Toronto, ON, Canada, ³Hospital for SickKids, Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰UNICAMP, Campinas, Brazil, ¹¹University of California San Francisco, San Rafael, CA, ¹²Institute for Work & Health, Toronto, ON, Canada, ¹³Hospital for SickKids, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with SLE [prevalence of 38% (range: 20%-80%)]. The exact mechanisms underlying CI is complex and multifactorial.…
Abstract Number: 1477 • ACR Convergence 2023
Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Nikita Stempniewicz¹, Andrea Steffens², Kimvi Kim¹, Christopher Bell³, Mary DuCharme², Helen Trenz² and David Singer¹, ¹GlaxoSmithKline, Philadelphia, PA, ²Optum, Eden Prairie, MN, ³GlaxoSmithKline, US Value Evidence and Outcomes, Durham, NC
Background/Purpose: Herpes zoster (HZ) is characterized by a painful dermatomal rash and is associated with increased healthcare costs and reduced quality of life. Systemic lupus…
Abstract Number: 1495 • ACR Convergence 2023
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Samik Basu¹, Daniel Nunez¹, Darshil Patel¹, Jenell Volkov¹, Zachary Vorndran¹, Steven Wong¹, Andreas Mackensen² and Georg Schett³, ¹Cabaletta Bio, Philadelphia, PA, ²Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a ground-breaking emerging treatment modality for severe refractory systemic lupus erythematosus (SLE) and has shown…
Abstract Number: 1579 • ACR Convergence 2023
Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Natalie McCormick¹, Chio Yokose¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 1852 • ACR Convergence 2023
Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus
Sebastian Bruera¹, Yinan Huang², Savannah Bowman¹, Maria Suarez-Almazor³, Grace Lo¹, Maria A. Lopez-Olivo⁴ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, Oxford, MS, ³MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus are at an increased risk of infections from the human papillomavirus (HPV) and subsequently HPV-mediated malignancies and genital warts.…
Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Yuichiro fujieda¹, Kodai Sakiyama¹, Nobuya Abe¹, Ryo Hisada¹, Michihito Kono¹, Masaru Kato¹, Olga Amengual², Khin Khin Tha³, Hisashi Shirakawa⁴ and Tatsuya Atsuma⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto, Japan, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…
Abstract Number: 2276 • ACR Convergence 2023
Patient Reported Impact of Lupus on Quality of Life
Beth Schneider, MyHealthTeam, San Francisco, CA
Background/Purpose: Research was undertaken to better understand how people living with lupus describe its sum total impact on their lives including work, challenges with relationships…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].